JPMorgan Chase & Co’s Kinnate Biopharma Inc. Common Stock KNTE Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-24,721
| Closed | -$65.8K | – | 6679 |
|
|
2024
Q1 | $65.8K | Buy |
24,721
+24,658
| +39,140% | +$65.6K | ﹤0.01% | 4877 |
|
|
2023
Q4 | $149 | Sell |
63
-8,811
| -99% | -$20.8K | ﹤0.01% | 6042 |
|
|
2023
Q3 | $12.4K | Buy |
8,874
+7,338
| +478% | +$10.3K | ﹤0.01% | 5265 |
|
|
2023
Q2 | $4.65K | Sell |
1,536
-22,344
| -94% | -$67.7K | ﹤0.01% | 5288 |
|
|
2023
Q1 | $149K | Buy |
23,880
+5,962
| +33% | +$37.2K | ﹤0.01% | 4480 |
|
|
2022
Q4 | $109K | Sell |
17,918
-1,156
| -6% | -$7.03K | ﹤0.01% | 4466 |
|
|
2022
Q3 | $228K | Buy |
19,074
+1,567
| +9% | +$18.7K | ﹤0.01% | 4113 |
|
|
2022
Q2 | $221K | Sell |
17,507
-4,363
| -20% | -$55.1K | ﹤0.01% | 4275 |
|
|
2022
Q1 | $246K | Buy |
21,870
+3,756
| +21% | +$42.2K | ﹤0.01% | 4346 |
|
|
2021
Q4 | $321K | Buy |
18,114
+4,696
| +35% | +$83.2K | ﹤0.01% | 4297 |
|
|
2021
Q3 | $309K | Buy |
13,418
+5,271
| +65% | +$121K | ﹤0.01% | 4206 |
|
|
2021
Q2 | $189K | Buy |
8,147
+3,079
| +61% | +$71.4K | ﹤0.01% | 4525 |
|
|
2021
Q1 | $158K | Buy |
+5,068
| New | +$158K | ﹤0.01% | 4531 |
|